Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

Gadolinium based contrast agents (GBCAs) used in MRI causes gadolinium retention in the brain, posing possible patient safety issues. Jeff Zagoudis

Gadolinium-based contrast agents (GBCAs) used in MRI causes gadolinium retention in the brain, skin and bone. However, there have not been any large-scale studies to determine if this presents long-term patient safety issues.

 

Blog | Magnetic Resonance Imaging (MRI) | December 15, 2017 | Dave Fornell

Over the past couple years covering the news about gadolinium-based contrast agent (GBCA) retention in the brain,...

Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017

December 12, 2017 — Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance...

Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017

December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring...

Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017

Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed...

Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017

October 10, 2017 — Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de...

Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell

Over the past decade, several clinical studies have shown gadolinium-based...

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017

September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC)...

FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents
News | Contrast Media | September 07, 2017

September 7, 2017 — The U.S. Food and Drug Administration (FDA) held a meeting of the Medical Imaging Drugs Advisory...

FDA Approves Guerbet's Dotarem for Pediatric Patients Younger Than Two Years
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017

September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem...

European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017

August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of...

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017

August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in...

Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell

Here are several updates in medical imaging ...

Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017

July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products:...

ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017

July 17, 2017 — The American College of Radiology (ACR) recently revised its authoritative guide for the safe and...

GE Healthcares imaging agent Visipaque, iodixanol, is now cleared for use with cardiac CT angiography, CCTA
Technology | CT Angiography (CTA) | June 16, 2017

June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s ...

FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017

May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based...

Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017

May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...

Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017

May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based...

Experience at 3 Sites Utilizing Syringe-Less Contrast Injectors
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017

Improving Efficiency and Reducing Waste

The volume of computed tomography (CT) imaging exams continues to...

PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017

March 13, 2017 — The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently...